A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Unfractionated heparin in Pulmonary Embolism, sponsored by Bayer. Completed at 31 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-01-23.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing rivaroxaban in Pulmonary Embolism — 4 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Pulmonary Embolism.
Among the 20 studies testing rivaroxaban in Pulmonary Embolism, this one is the 18th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 5th registered.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
Browse Pulmonary Embolism studies →4 of the 20 studies testing rivaroxaban in Pulmonary Embolism are open now, in 8 countries. Recruiting first, the newest first:
Prof. Stavros Konstantinides, MD · Sites in Austria, Germany
Ages 18–85
Medical University of Gdansk · Sites in Poland
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
Drahomir Aujesky · Sites in Belgium, Canada, France and 2 more countries
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8 · Phase 4 6
First in 2004; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 174 across 429 interventional studies indexed under Pulmonary Embolism.
Median enrollment 241 across the 20 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
15 studies in Pulmonary Embolism by Bayer: none open now, none under way, none of them phase 3. Of 14 finished, 4 (29%) have results posted.
Among the 15 studies in Pulmonary Embolism by Bayer, this one is one of 2 that started in 2012, is one of 4 in phase 3, and was the 5th registered.
Bayer’s Pulmonary Embolism studies by the year they started, since 2004.
2 of the studies testing rivaroxaban in Pulmonary Embolism that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611319Phase 3Prof. Stavros Konstantinides, MDENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | 2027-03 |
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing rivaroxaban in Pulmonary Embolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 15 in Pulmonary Embolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in the treatment of pulmonary embolism (PE) and the prevention of the occurrence and the recurrence of deep vein thrombosis (DVT) or PE in Japanese patients with acute symptomatic PE with or without symptomatic DVT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Unfractionated heparin
Drug: Warfarin
15 mg twice daily for 21 days, followed by 15 mg once daily
To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
Number of participants with newly onset of symptomatic venous thromboembolism (VTE)
Time frame: Up to 12 months
Number of clinically relevant bleedings
Time frame: Up to 2 days after last dose
Number of participants with improvement in thrombotic burden
Time frame: At week 3
Number of participants with deterioration in thrombotic burden
Time frame: Up to 12 months
Number of participants with the composite of newly onset of symptomatic VTE or asymptomatic deterioration of thrombus
Time frame: Up to 12 months
The record gives a start of Feb 2012, a primary completion of Oct 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban